Reviewing Avita Medical (RCEL) and Its Competitors

Avita Medical (NASDAQ:RCEL) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Avita Medical to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Avita Medical and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avita Medical	1	1	5	0	2.57
Avita Medical Competitors	4242	10457	18169	819	2.46

Avita Medical presently has a consensus price target of $12.20, suggesting a potential downside of 26.99%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 22.82%. Given Avita Medical’s rivals higher probable upside, analysts clearly believe Avita Medical has less favorable growth aspects than its rivals.

Risk and Volatility

Avita Medical has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, Avita Medical’s rivals have a beta of 2.52, indicating that their average share price is 152% more volatile than the S&P 500.

Profitability

This table compares Avita Medical and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avita Medical	-56.96%	N/A	-78.53%
Avita Medical Competitors	-278.47%	-150.38%	-22.01%

Institutional & Insider Ownership

27.7% of Avita Medical shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 2.2% of Avita Medical shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Avita Medical and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Avita Medical	$71.61 million	-$48.59 million	-11.60
Avita Medical Competitors	$1.90 billion	$138.15 million	11.14

Avita Medical’s rivals have higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Avita Medical rivals beat Avita Medical on 9 of the 13 factors compared.

About Avita Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.